Revisión sistemática sobre la eficacia de racecadotrilo en el tratamiento de la diarrea aguda

  1. J.I. Emparanza Knörr
  2. I. Ozcoidi Erro
  3. M.C. Martínez Andueza
  4. M.T. Callén Blecua
  5. E. Alústiza Martínez
  6. I. Aseguinolaza Iparraguirre
Zeitschrift:
Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

ISSN: 1695-4033 1696-4608

Datum der Publikation: 2008

Ausgabe: 69

Nummer: 5

Seiten: 432-438

Art: Artikel

DOI: 10.1157/13127998 DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

Zusammenfassung

Objective To estimate, through a systematic review of the literature, the efficacy of racecadotril in the treatment of acute diarrhoea. Material and methods Randomised trials carried out in children comparing racecadotril with placebo in terms of diarrhoea recovery, stools output and adverse effects were selected. Electronic databases (Medline, EMBASE, CENTRAL, CINAHL, mRCT, Pascal) and bibliographies of retrieved articles were searched, and the drug developer was contacted. Two authors independently assessed the quality of the retrieved articles and extracted the data. Results Two small sample size randomised trials (135 and 172 children) of moderate quality were selected. They included children with less than five days diarrhoea and aged between 3 months and 4 years. There was no difference in the proportion of children who recovered by day 5 (RR = 0.73, CI95 % 0.29 to 1.81), although the stools volume during the first 48 hours was less in the racecadotril group (SMD = -0.65, CI95 % -0.88 to - 0.52). There is no difference in the risk of vomiting (RR = 1.16, CI95 % 0.64 to 2.12). Conclusion The proportion of recoveries by the 5th day is the same, although the stool volumes during the first 48 hours are less in the racecadotril treated children. It would be interesting to study the efficacy in a primary care setting assessing the cure rate, the stool volumes and the admission rate to elucidate if there is room for this drug.